SCHEMBL20500282

SCHEMBL20500282

CC(=O)OCC(CC(COP(=O)(O)O)NCCCCCC1SC[C@@H]2NC(=O)N[C@H]12)OC(C)=O

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PLCD1 P51178 1/20 0.46
▸ TDP1 Q9NUW8 5/20 0.45
▸ CNR2 P34972 2/20 0.43
▸ HLCS P50747 6/20 0.42
▸ F2 P00734 1/20 0.42
▸ PRSS1 P07477 1/20 0.42
▸ PRSS2 P07478 1/20 0.42
▸ PRSS3 P35030 1/20 0.42
▸ TPSAB1 Q15661 1/20 0.42
▸ MEN1 O00255 1/20 0.41
▸ ABL1 P00519 1/20 0.41
▸ LMNA P02545 1/20 0.41
▸ PKM P14618 1/20 0.41
▸ IDE P14735 1/20 0.41
▸ MAPK1 P28482 1/20 0.41
▸ KMT2A Q03164 1/20 0.41
▸ RIN1 Q13671 1/20 0.41
▸ L3MBTL1 Q9Y468 1/20 0.41
▸ HPSE Q9Y251 1/20 0.41
▸ CNR1 P21554 3/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20500246 0.98 PLCD1 (0.44) PLCD1TDP1CNR2HLCSF2
SCHEMBL22529457 0.88 PLCD1 (0.54) PLCD1TDP1CNR2F2PRSS1
SCHEMBL22712998 0.88 TDP1 (0.48) PLCD1TDP1CNR2HLCSF2
SCHEMBL20500226 0.82 PLCD1 (0.48) PLCD1TDP1CNR2HLCSF2
SCHEMBL3614161 0.79 PLCD1 (0.59) PLCD1TDP1CNR2F2PRSS1
SCHEMBL1270689 0.79 PLCD1 (0.44) PLCD1TDP1CNR2HLCSF2
SCHEMBL487698 0.79 PLCD1 (0.44) PLCD1TDP1CNR2HLCSF2
SCHEMBL22712999 0.78 TDP1 (0.48) PLCD1TDP1CNR2F2PRSS1
SCHEMBL486814 0.78 PLCD1 (0.56) PLCD1TDP1CNR2F2PRSS1
SCHEMBL20500280 0.76 TDP1 (0.43) PLCD1TDP1CNR2HLCSF2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3952904-A1 LIPID-BASED NANOPARTICLES AND USE OF SAME IN OPTIMIZED INSULIN DOSING REGIMENS SDG, Inc. (US) 2022-02-16 — — EP claimed
WO-2020210697-A1 LIPID-BASED NANOPARTICLES AND USE OF SAME IN OPTIMIZED INSULIN DOSING REGIMENS SDG, INC. (US) 2020-10-15 — — WO claimed
WO-2018169954-A1 LIPID-BASED NANOPARTICLES WITH ENHANCED STABILITY SDG, INC. (US) 2018-09-20 — — WO claimed
Send feedback